The complexity of the brain makes drug discovery and development for diseases of the central nervous system (CNS) a huge challenge. As a result, many drugs never make it to market because they demonstrate an unexpected lack of efficacy or unexpected off-target effects. This comes at considerable cost to the pharmaceutical industry and has contributed to a decline in CNS drug development in recent years.
Yet, the demand for new CNS treatments is increasing and is likely to continue to do so.
The team at The Science Behind are able to provide an innovative service, developed by Dr Isabella Premoli*, using transcranial magnetic stimulation (TMS) combined with electroencephalography (EEG) and electromyography (EMG) that offers an array of electro-diagnostic markers (EDM) to assess human brain excitability and functionality in health and disease.
Used in early-stage and first-in-human clinical trials we can obtain pharmacodynamic EDM for biological target engagement.
Our Research Team includes combined pharmacology and neuroscience expertise and includes work with a number of pharmaceuticals, specifically in this relatively new and exciting area of drug development.
Our services, for those pharmaceutical organisations looking to evaluate i) in-vivo markers for pharmacological activity and ii) in-vivo markers for specific biological processes include:
- Design of TMS-EDM protocol
- Delivery of the study
- Analysis of the data
- Report back of the findings
We are happy to work directly with pharmaceutical companies or with preferred contract research organisations (CROs) and we also welcome direct collaboration with CROs as part of a contracted study programme.
*Download Dr Isabella Premoli’s research paper ‘TMS as a pharmacodynamic indicator of cortical activity of a novel anti-epileptic drug, XEN1101’